These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1127 related items for PubMed ID: 28244290

  • 1. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, Jeon D.
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [Abstract] [Full Text] [Related]

  • 2. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T, Lee SJ, Jeon D, Lee HY, Kim HJ, Kang BH, Mok J.
    J Korean Med Sci; 2021 Jul 05; 36(26):e174. PubMed ID: 34227261
    [Abstract] [Full Text] [Related]

  • 3. Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.
    Rahman A, Ferdous SS, Ahmed S, Rahman SMM, Uddin MKM, Pholwat S, Gratz J, Houpt E, Banu S.
    Antimicrob Agents Chemother; 2017 Sep 05; 61(9):. PubMed ID: 28630193
    [Abstract] [Full Text] [Related]

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 5. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Pang Y, Zhu D, Zheng H, Shen J, Hu Y, Liu J, Zhao Y.
    BMC Infect Dis; 2017 Nov 06; 17(1):711. PubMed ID: 29110640
    [Abstract] [Full Text] [Related]

  • 6. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T, Sun F, Li Y, Chen J, Chen X, Li R, Ge S, Zhao Y, Zhang W.
    BMC Infect Dis; 2021 Feb 17; 21(1):183. PubMed ID: 33596848
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
    Sengstake S, Bergval IL, Schuitema AR, de Beer JL, Phelan J, de Zwaan R, Clark TG, van Soolingen D, Anthony RM.
    BMC Infect Dis; 2017 Jul 12; 17(1):491. PubMed ID: 28697808
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
    Kuhlin J, Smith C, Khaemraev A, Tigay Z, Parpieva N, Tillyashaykhov M, Achar J, Hajek J, Greig J, du Cros P, Moore D.
    Int J Tuberc Lung Dis; 2018 May 01; 22(5):544-550. PubMed ID: 29663960
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
    Ngabonziza JCS, Diallo AB, Tagliani E, Diarra B, Kadanga AE, Togo ACG, Thiam A, de Rijk WB, Alagna R, Houeto S, Ba F, Dagnra AY, Ivan E, Affolabi D, Schwoebel V, Trebucq A, de Jong BC, Rigouts L, Daneau G, “Union short MDR-TB regimen study group”.
    PLoS One; 2017 May 01; 12(10):e0187211. PubMed ID: 29088294
    [Abstract] [Full Text] [Related]

  • 16. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
    Juma SP, Maro A, Pholwat S, Mpagama SG, Gratz J, Liyoyo A, Houpt ER, Kibiki GS, Mmbaga BT, Heysell SK.
    BMC Infect Dis; 2019 Feb 07; 19(1):129. PubMed ID: 30732572
    [Abstract] [Full Text] [Related]

  • 17. Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015.
    Mansjo M, Werngren J, Hoffner S.
    Int J Mycobacteriol; 2017 Feb 07; 6(2):156-161. PubMed ID: 28559517
    [Abstract] [Full Text] [Related]

  • 18. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.
    Clin Infect Dis; 2008 Aug 15; 47(4):496-502. PubMed ID: 18611154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.
    Clin Infect Dis; 2007 Nov 15; 45(10):1290-5. PubMed ID: 17968823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.